1. Home
  2. BRID vs BCAB Comparison

BRID vs BCAB Comparison

Compare BRID & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bridgford Foods Corporation

BRID

Bridgford Foods Corporation

HOLD

Current Price

$8.08

Market Cap

72.8M

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$0.32

Market Cap

71.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRID
BCAB
Founded
1932
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Medicinal Chemicals and Botanical Products
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.8M
71.6M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
BRID
BCAB
Price
$8.08
$0.32
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$1.00
AVG Volume (30 Days)
3.4K
2.0M
Earning Date
01-28-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$227,364,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.24
$0.24
52 Week High
$10.77
$1.43

Technical Indicators

Market Signals
Indicator
BRID
BCAB
Relative Strength Index (RSI) 54.89 26.64
Support Level $7.65 $0.40
Resistance Level $8.50 $0.82
Average True Range (ATR) 0.26 0.11
MACD 0.06 -0.04
Stochastic Oscillator 66.13 0.79

Price Performance

Historical Comparison
BRID
BCAB

About BRID Bridgford Foods Corporation

Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The business segments are; the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, and mass merchandise and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Share on Social Networks: